Table 1.
Relationship between R-ATG induction therapy development of PTLD.
| Odds ratio | p value | 95% Confidence Interval | |
|---|---|---|---|
| R-ATG versus IL2-RA induction | 1.48 | .02 | 1.04 to 2.11 |
| Tacrolimus versus cyclosporine | 0.87 | .53 | 0.57 to 1.33 |
| Sex: | |||
| Male | 1.08 | .64 | 0.77 to 1.51 |
| CMV: | |||
| Positive | 0.88 | .48 | 0.62 to 1.25 |
| EBV: | |||
| Positive | 0.69 | .02 | 0.49 to 0.95 |
| Recipient age | 0.98 | .08 | 0.97 to 1.00 |
| Donor age | 0.99 | .61 | 0.98 to 1.00 |
| HLA mismatch | 0.92 | .11 | 0.84 to 1.01 |
| Steroids maintenance: | |||
| Yes | 1.50 | .14 | 0.86 to 2.64 |
R-ATG: Rabbit antithymocyte globulin; IL2-RA: interleukin-2 receptor antagonist; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; HLA: Human leucocyte antigen.